Nerve growth factor concentrations in the synovial fluid from healthy dogs and dogs with secondary osteoarthritis

2011 ◽  
Vol 24 (04) ◽  
pp. 279-284 ◽  
Author(s):  
M. Isola ◽  
V. Ferrari ◽  
F. Stabile ◽  
D. Bernardini ◽  
P. Carnier ◽  
...  

SummaryObjective: To measure the concentrations of nerve growth factor (NGF) in the synovial fluid from normal dogs and dogs with osteoarthritis (OA) secondary to common joint disorders.Methods: Nerve growth factor synovial concentrations were measured by ELISA assay in 50 dogs divided into three groups: 12 healthy, 16 affected by acute lameness within seven days before enrolment, and 22 with chronic lameness persisting by more than one month before enrolment and accompanied by radiological signs of OA. Both acute and chronic lameness were secondary to orthopaedic diseases involving the shoulder, elbow and stifle joints. Nerve growth factor synovial concentrations were compared between means for healthy and acute groups and between the three groups using an F-test. Significance level was set at p ±0.05.Results: Nerve growth factor was detected in all canine synovial fluid samples. However, the mean synovial NGF concentration of healthy dogs (3.65 ± 2.18 pg/ml) was not significantly different from the mean value in dogs with acute lameness (6.45 ± 2.45 pg/ml) (p ± 0.79). Conversely, the mean synovial NGF concentration in dogs with chronic lameness (20.19 ± 17.51 pg/ml) was found to be significantly higher than that found in healthy dogs (p ±0.01).Clinical significance: This study demonstrates for the first time the presence of NGF in canine synovial fluid and its increased concentrations in dogs with chronic lameness compared to healthy dogs and dogs with acute lameness. The association between chronic lameness and raised synovial concentrations may suggest an involvement of NGF in OA inflammation and chronic pain.

1992 ◽  
Vol 35 (3) ◽  
pp. 351-355 ◽  
Author(s):  
Luigi Aloe ◽  
Marco A. Tuveri ◽  
Ugo Carcassi ◽  
Rita Levi-Montalcini

2001 ◽  
Vol 05 (03) ◽  
pp. 193-203 ◽  
Author(s):  
Boonsin Buranapanitkit ◽  
Zhuqing Qu ◽  
Morey M. Moreland ◽  
Alan Geater ◽  
George Somogyi ◽  
...  

The effects of growth factors on denervated muscle atrophy in mouse gastrocnemius muscle were studied by morphometric, physiologic and histologic methods. Fifteen mice were randomized into three groups: intact, denervated-insulin-like growth factor-1-treated (D-IGF-1) and denervated-nerve growth factor-treated (D-NGF). In denervated animals, the left sides were used as a control by injecting balanced salt solution (HBSS), while the right sides were injected with growth factors. The mean wet weight and the mean wet weight/body weight were significantly higher in D-IGF-1 muscles compared to the D-NGF and D-HBSS muscles, but were not different from the muscle of intact controls. Physiologic testing showed that the mean maximal tetanic twitch strength and the mean maximal fast twitch strength were also significantly higher in the D-IGF-1 muscles than in the D-NGF and D-HBSS muscles. Mean time-to-peak was significantly only decreased in the D-NGF muscles. Histological studies found that the mean percentage of type 2 fiber was significantly higher in D-NGF muscles. The types I and II mean diameters in the D-IGF-1 muscles were larger than in the D-NGF and D-HBSS muscles, but all denervated muscles had higher interstitial fibrosis than the intact controls. In conclusion, we show that IGF-1 can effectively retard denervated muscle atrophy by increasing types I and II fibre muscle diameter. However, IGF-1 cannot prevent interstitial fibrosis in the denervated muscle.


Autoimmunity ◽  
1996 ◽  
Vol 24 (1) ◽  
pp. 1-9 ◽  
Author(s):  
Eleni Dicou ◽  
Serge Perrot ◽  
Charles J. Menkes ◽  
Charles Masson ◽  
Veronique Nerriere

2019 ◽  
Vol 12 ◽  
pp. 117956111986490
Author(s):  
Sameer Trivedi ◽  
Pranab Patnaik ◽  
Yashpal Ramole ◽  
Faiz Ahmed Khan ◽  
Ragini Srivastava ◽  
...  

Background: This study compared urinary and serum nerve growth factor levels and serum C-reactive protein levels in patients with overactive bladder, before and after treatment with antimuscarinic agents, to evaluate their diagnostic and therapeutic importance. Methods: This was a prospective case-control study conducted between February 2014 and December 2014 which included patients with a confirmed diagnosis of overactive bladder (overactive bladder group) and healthy controls (control group). All patients visiting urology out-patient department with urgency, frequency, and urge incontinence were assessed for overactive bladder and, if eligible, were enrolled in the study. Biomarkers were evaluated before in both groups and after antimuscarinic treatment in the overactive bladder group. Results: Overall, 80 participates were enrolled (overactive bladder, n = 40; control, n = 40). The mean age was not different between the two groups (overactive bladder, 48.6 years; control, 46.9 years [ P = 1.01]) and females were more in both the groups (60% and 55%, respectively). The majority (70%) of patients presented with frequency and urgency. After 3 months of treatment with antimuscarinics, the mean overactive bladder symptom score decreased significantly from 8.4 to 4.85 ( P < .001). The mean urinary and serum nerve growth factor levels and serum C-reactive protein levels also decreased significantly from baseline after 3 months of treatment with antimuscarinics (24.78 pg/mL, 22.46 pg/mL, 0.89 mg/L, respectively; P < .0001). Conclusions: Measurement of urinary and serum nerve growth factor levels has diagnostic and therapeutic potential in patients with overactive bladder.


Planta Medica ◽  
2011 ◽  
Vol 77 (05) ◽  
Author(s):  
ND Chaurasiya ◽  
R Sahu ◽  
V Samoylenko ◽  
M Ilias ◽  
LA Walker ◽  
...  

Pneumologie ◽  
2012 ◽  
Vol 66 (06) ◽  
Author(s):  
K Seidler ◽  
A Sydykov ◽  
S Müller-Brüsselbach ◽  
R Müller ◽  
N Weißmann ◽  
...  

2014 ◽  
Vol 4 (1_suppl) ◽  
pp. s-0034-1376539-s-0034-1376539
Author(s):  
E. Krock ◽  
D. H. Rosenzweig ◽  
A. J. Chabot-Dore ◽  
P. Jarzem ◽  
M. H. Weber ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document